News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.
Locate Bio, a UK-based orthobiologics company, has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft.
uBriGene is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from Mustang Bio.
Moderna has reported interim phase 1/2 data for mRNA-3927, its mRNA therapy targeted at propionic acidemia (PA).